Technoderma Medicines' TDM-180935, a topical JAK-1/TYK-2 inhibitor, demonstrated efficacy in a Phase 2a trial for atopic dermatitis, with the 2% formulation showing the most promise.
Viva's portfolio companies have made notable progress in biopharmaceutical innovation, including funding achievements, clinical trial advancements, and strategic collaborations aimed at developing novel therapies for various diseases.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.